Aclaris Therapeutics, Inc.

NASDAQ:ACRS

Biotechnology

Healthcare
$3.50 +0.57%

+$0.03 today

Market cap
$555.14M
Beta
0.80
P/E (TTM)
-8.2
EPS (TTM)
-$0.54
52W Low $1.34High $5.15

Volume 2.94M

Average 1.40M

ACRS Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Aclaris Therapeutics, Inc.NASDAQ: ACRS

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 80.2%

Gross margin was 80.2% in Q1 FY2026, up 15.0 pp from a year earlier. On a trailing-twelve-month basis it was 76.3%, up 55.8 pp year over year. Over 3 fiscal years it widened by 13.5 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
80.2%-81.8 pp QoQ
Last fiscal yearDec 2025
73.3%-11.8 pp YoY
LTMMar 2026
76.3%+55.8 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+15.0 pp——
1 year-11.8 pp——
3 years+13.5 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
73.3%
Year-over-year change
-11.8pp

Gross Margin vs competitors

How ACRS compares with its peers on the latest reported figures

  • ACRS's LTM Mar 2026 gross margin of 76.3% is the 3rd highest of the 5 companies compared; the peer median is 64.3%.
  • Its year-over-year change of +55.8 pp is the 2nd highest of 4, against a peer median of -7.7 pp.
  • Over three fiscal years its change of +13.5 pp compares with a peer median of +862.2 pp.
ACRS Competitors Peer median
Gross Margin for ACRS and competitors
Company Period LTM level YoY 3-year change
ANABAnaptysBio, Inc.LTM Mar 2026116.4% +166.6 pp+862.2 pp
ALMSAlumis Inc. Common StockLTM Jun 202688.2% -7.7 pp—
ACRSAclaris Therapeutics, Inc.LTM Mar 202676.3% +55.8 pp+13.5 pp
ATTOAttovia Therapeutics, Inc.FY202540.4% ——
IFRXInflaRx N.V.LTM Mar 2026-24646.3% -22352.6 pp—
TRAXFirst Tracks Biotherapeutics IncFY2025— ——
MLTXMoonLake ImmunotherapeuticsFY2025— ——
ODTXOdyssey Therapeutics, Inc.—— ——
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024— ——
IMUXImmunic, Inc.FY2025— ——
ALDXAldeyra Therapeutics, Inc.FY2025— ——
Peer median (excluding ACRS) 64.3%-7.7 pp+862.2 pp

Competitors are the stored peer set for ACRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.76M29.75M31.25M18.72M7.83M
Cost of Revenue4.71M11.96M18.08M2.79M2.09M
Gross Profit2.05M17.79M13.17M15.93M5.74M
Gross Margin30.3%59.8%42.1%85.1%73.3%
Research & Development43.81M77.81M98.38M33.59M52.65M
Selling, General & Admin23.62M25.13M31.1M22.2M21.97M
Operating Expenses91.77M107.65M110.53M157.86M82.11M
Depreciation & Amortization923K797K863K807K454K
EBITDA(64.46M)(84.36M)(115.45M)(51.72M)(64.47M)
EBITDA Margin-953.4%-283.5%-369.5%-276.3%-823.8%
Operating Income(89.72M)(89.85M)(97.36M)(141.93M)(76.38M)
Operating Margin-1327.1%-302.0%-311.6%-758.2%-975.9%
Interest Income0007.95M7.64M
Interest Expense00000
Other Income / Expenses(1.14M)2.95M8.51M9.87M11.45M
Income Before Tax(90.87M)(86.91M)(88.85M)(132.07M)(64.92M)
Pre-Tax Margin-1344.0%-292.1%-284.3%-705.5%-829.6%
Income Tax Expense00(367K)00
Net Income(90.87M)(86.91M)(88.48M)(132.07M)(64.92M)
Net Margin-1344.0%-292.1%-283.1%-705.5%-829.6%
EPS (Basic)(1.60)(1.33)(1.27)(1.71)(0.53)
EPS (Diluted)(1.60)(1.33)(1.27)(1.71)(0.53)
Weighted Avg Shares56.73M65.21M69.81M77.3M122.66M
Weighted Avg Shares (Diluted)56.73M65.21M69.81M77.3M122.66M

Aclaris Therapeutics, Inc.

NASDAQ:ACRS

Intrinsic Alpha fair value

Locked

Current Price

$3.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.